Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension Studies.
Diaz N, Juarez M, Cancrini C, Heeg M, Soler-Palacín P, Payne A, Johnston GI, Helmer E, Cain D, Mann J, Yuill D, Conti F, Di Cesare S, Ehl S, Garcia-Prat M, Maccari ME, Martín-Nalda A, Martínez-Gallo M, Moshous D, Santilli V, Semeraro M, Simonetti A, Suarez F, Cavazzana M, Kracker S. Diaz N, et al. Among authors: payne a. J Immunol. 2020 Dec 1;205(11):2979-2987. doi: 10.4049/jimmunol.2000326. Epub 2020 Oct 28. J Immunol. 2020. PMID: 33115853 Clinical Trial.
Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.
Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, Buckley CD, Bowman SJ, Priori R, Valesini G, Juarez M, Fahy WA, Fisher BA, Payne A, Allen RA, Barone F. Nayar S, et al. Among authors: payne a. Ann Rheum Dis. 2019 Feb;78(2):249-260. doi: 10.1136/annrheumdis-2017-212619. Epub 2018 Nov 24. Ann Rheum Dis. 2019. PMID: 30472652 Free PMC article.
Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ.
Allen RA, Brookings DC, Powell MJ, Delgado J, Shuttleworth LK, Merriman M, Fahy IJ, Tewari R, Silva JP, Healy LJ, Davies GCG, Twomey B, Cutler RM, Kotian A, Crosby A, McCluskey G, Watt GF, Payne A. Allen RA, et al. Among authors: payne a. J Pharmacol Exp Ther. 2017 Jun;361(3):429-440. doi: 10.1124/jpet.116.237347. Epub 2017 Apr 25. J Pharmacol Exp Ther. 2017. PMID: 28442583
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ. Juarez M, et al. Among authors: payne a. Rheumatology (Oxford). 2021 Mar 2;60(3):1364-1375. doi: 10.1093/rheumatology/keaa410. Rheumatology (Oxford). 2021. PMID: 32949140 Clinical Trial.
Atropisomeric small molecule Bcl-2 ligands: determination of bioactive conformation.
Porter J, Payne A, Whitcombe I, de Candole B, Ford D, Garlish R, Hold A, Hutchinson B, Trevitt G, Turner J, Edwards C, Watkins C, Davis J, Stubberfield C. Porter J, et al. Among authors: payne a. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1767-72. doi: 10.1016/j.bmcl.2009.01.071. Epub 2009 Jan 27. Bioorg Med Chem Lett. 2009. PMID: 19217289
Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.
Reuberson J, Horsley H, Franklin RJ, Ford D, Neuss J, Brookings D, Huang Q, Vanderhoydonck B, Gao LJ, Jang MY, Herdewijn P, Ghawalkar A, Fallah-Arani F, Khan AR, Henshall J, Jairaj M, Malcolm S, Ward E, Shuttleworth L, Lin Y, Li S, Louat T, Waer M, Herman J, Payne A, Ceska T, Doyle C, Pitt W, Calmiano M, Augustin M, Steinbacher S, Lammens A, Allen R. Reuberson J, et al. Among authors: payne a. J Med Chem. 2018 Aug 9;61(15):6705-6723. doi: 10.1021/acs.jmedchem.8b00521. Epub 2018 Jul 19. J Med Chem. 2018. PMID: 29952567
1,334 results